Table 1. The effect of specific influx... | American Society of Hematology

Table 1.

The effect of specific influx and efflux inhibitors on IUR of imatinib and nilotinib (ng per 200 00 cells) on the total patient pool and in the low and high IC50^imatinib cohorts

	Imatinib, 2 μM									Nilotinib, 2 μM
	No inhibitor	Prazosin	Procainamide	PSC833	FTC	No inhibitor	Prazosin	Procainamide	PSC833	FTC
Total	24.35	8.57*	14.56	16.56	25.31	32.97	32.8	33.47	17.13*	32.25
Low IC50^imatinib	35.41	9.00*	14.78*	25.47	42.52	40.32	37.551	42.38	22.20	42.07
High IC50^imatinib	15.13†	8.21*	14.37	10.6	13.8†	28.08	29.00	27.52	14.14*	25.70

	Imatinib, 2 μM									Nilotinib, 2 μM
	No inhibitor	Prazosin	Procainamide	PSC833	FTC	No inhibitor	Prazosin	Procainamide	PSC833	FTC
Total	24.35	8.57*	14.56	16.56	25.31	32.97	32.8	33.47	17.13*	32.25
Low IC50^imatinib	35.41	9.00*	14.78*	25.47	42.52	40.32	37.551	42.38	22.20	42.07
High IC50^imatinib	15.13†	8.21*	14.37	10.6	13.8†	28.08	29.00	27.52	14.14*	25.70

Significant difference at the .05 level in comparison with no inhibitor.

†

Significant difference at the .05 level between low and high IC50^imatinib groups.

View Large

This Feature Is Available To Subscribers Only